Flutiform - Results of Safety Study
Frank Condella, CEO of SkyePharma said, 'The results of this study are as we expected and represent a significant milestone achieved in the FlutiformTM development programme. We continue to make good progress towards the approval of this exciting product.'
For further information please contact:
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer +44 207 491 1777
Peter Grant, Finance Director
Financial Dynamics (London enquiries) David Yates / Deborah Scott +44 207 831 3113
Trout Group (US enquiries) Christine Labaree / Seth Lewis +1 617 583 1308
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Company has eleven approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com.
Posted: November 2007